Oct 7, 2026 01:59AM
Oct 1, 2026 02:00AM
Oct 1, 2026 02:00AM
Aug 25, 2026 06:59AM
Aug 14, 2026 08:19AM
Jun 1, 2026 07:26AM
Jun 1, 2026 06:55AM Oculis Holding AG (OCS) PT Lowered to $26 at H.C. Wainwright
May 29, 2026 03:06PM
May 29, 2026 03:05PM
May 29, 2026 02:54PM
May 7, 2026 05:59AM
May 7, 2026 04:57AM
May 1, 2026 04:00AM
Jan 6, 2026 08:00AM Oculis receives FDA breakthrough therapy designation for optic neuritis drug
Dec 19, 2025 07:42AM
Oct 7, 2025 06:39AM
Aug 22, 2025 05:33AM
Apr 15, 2025 03:01PM
Apr 10, 2025 08:04AM
Apr 10, 2025 08:00AM
Apr 1, 2025 04:00AM Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
Mar 13, 2025 06:41AM
Mar 12, 2025 09:18AM
Jan 7, 2025 06:52AM
Jan 6, 2025 02:12PM
Aug 28, 2024 06:43AM
Aug 27, 2024 04:00AM
Jun 11, 2024 06:42AM Oculis Holding AG (OCS) PT Raised to $30 at H.C. Wainwright
Jun 11, 2024 05:24AM
Jun 10, 2024 05:00AM
Jun 10, 2024 04:30AM
Apr 10, 2024 06:30AM
Dec 20, 2023 06:30AM
Aug 8, 2023 06:30AM
Aug 8, 2023 06:30AM OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Followin
Apr 26, 2023 07:04AM
Apr 26, 2023 07:00AM
Apr 26, 2023 07:00AM

334,268 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All